Ratings by Evercore ISI (Liisa Bayko)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/13/2026 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/25/2025 | CRISPR Therapeutics | CRSP | New Coverage | Outperform (N/A) |
54.32 (54.54) |
0.41% | Details | |
| 6/11/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/6/2025 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2025 | Savara | SVRA | Maintain | In Line (N/A) |
|
Details | ||
| 5/13/2025 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2025 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2025 | CRISPR Therapeutics | CRSP | Upgrade | Outperform (In Line) |
43.49 (54.54) |
25.41% | Details | |
| 1/13/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2024 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Carisma Therapeutics Inc | CARM | Downgrade | In Line (Outperform) |
0.69 (0.15) |
-78.26% | Details | |
| 11/13/2024 | Savara | SVRA | Downgrade | In Line (Outperform) |
3.83 (6.16) |
60.84% | Details | |
| 11/6/2024 | Editas Medicine | EDIT | Upgrade | Outperform (In Line) |
3.12 (3.24) |
3.85% | Details | |
| 10/31/2024 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2024 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2024 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2024 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | AN2 Therapeutics | ANTX | Downgrade | Underperform (In Line) |
2.64 (4.84) |
83.33% | Details | |
| 8/2/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/21/2024 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2024 | Aerovate Therapeutics Inc | AVTE | Downgrade | In Line (Outperform) |
24.62 (2.68) |
-89.11% | Details | |
| 6/3/2024 | Caribou Biosciences Inc. | CRBU | Downgrade | In Line (Outperform) |
2.88 (1.76) |
-38.89% | Details | |
| 5/30/2024 | Editas Medicine | EDIT | Maintain | In Line (N/A) |
|
Details | ||
| 5/28/2024 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2024 | AN2 Therapeutics | ANTX | Maintain | In Line (N/A) |
|
Details | ||
| 5/14/2024 | 89bio Inc. | ETNB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2024 | Carisma Therapeutics Inc | CARM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Vertex | VRTX | Upgrade | Outperform (In Line) |
397.58 (496.73) |
24.94% | Details | |
| 3/19/2024 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2024 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2024 | AN2 Therapeutics | ANTX | Downgrade | In Line (Outperform) |
20.00 (2.64) |
-86.8% | Details | |
| 2/6/2024 | Vertex | VRTX | Downgrade | In Line (Outperform) |
428.89 (397.58) |
-7.3% | Details | |
| 1/29/2024 | Savara | SVRA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2024 | CRISPR Therapeutics | CRSP | Maintain | In Line (N/A) |
|
Details | ||
| 1/5/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2023 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2023 | Caribou Biosciences Inc. | CRBU | New Coverage | Outperform (N/A) |
3.62 (2.88) |
-20.44% | Details | |
| 10/11/2023 | 89bio Inc. | ETNB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2023 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2023 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2023 | Travere Therapeutics | TVTX | New Coverage | Outperform (N/A) |
14.19 (56.81) |
300.35% | Details | |
| 7/6/2023 | Carisma Therapeutics Inc | CARM | New Coverage | Outperform (N/A) |
8.89 (0.69) |
-92.24% | Details | |
| 6/26/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/13/2023 | 89bio Inc. | ETNB | New Coverage | Outperform (N/A) |
21.19 (14.84) |
-29.97% | Details | |
| 6/6/2023 | Ultragenyx Pharma | RARE | Upgrade | Outperform (In Line) |
51.25 (33.39) |
-34.85% | Details | |
| 5/31/2023 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2023 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/19/2023 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2023 | Astria Therapeutics | ATXS | New Coverage | Outperform (N/A) |
11.44 (12.58) |
9.97% | Details | |
| 3/21/2023 | Altimmune | ALT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2023 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2023 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2023 | Altimmune | ALT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2022 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2022 | Editas Medicine | EDIT | Maintain | In Line (N/A) |
|
Details | ||
| 11/2/2022 | BioCryst Pharma | BCRX | Upgrade | Outperform (In Line) |
11.86 (10.00) |
-15.68% | Details | |
| 10/31/2022 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2022 | BioCryst Pharma | BCRX | Downgrade | In Line (Outperform) |
11.15 (10.00) |
-10.31% | Details | |
| 8/1/2022 | Innate Pharma S.A. | IPHA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2022 | Ultragenyx Pharma | RARE | Downgrade | In Line (Outperform) |
51.88 (33.39) |
-35.64% | Details | |
| 7/6/2022 | Enanta Pharmaceuticals | ENTA | Upgrade | Outperform (In Line) |
52.68 (14.58) |
-72.32% | Details | |
| 6/23/2022 | CRISPR Therapeutics | CRSP | Downgrade | In Line (Outperform) |
64.67 (43.49) |
-32.75% | Details | |
| 6/1/2022 | Enanta Pharmaceuticals | ENTA | Upgrade | In Line (Underperform) |
39.47 (14.58) |
-63.06% | Details | |
| 5/17/2022 | Aerovate Therapeutics Inc | AVTE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2022 | Aura Biosciences | AURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2022 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2022 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2022 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2022 | Editas Medicine | EDIT | Downgrade | In Line (Outperform) |
17.29 (3.12) |
-81.95% | Details | |
| 12/28/2021 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/23/2021 | Aura Biosciences | AURA | New Coverage | Outperform (N/A) |
19.63 (7.10) |
-63.83% | Details | |
| 8/5/2021 | Editas Medicine | EDIT | Upgrade | Outperform (Underperform) |
42.11 (17.29) |
-58.94% | Details | |
| 6/8/2021 | Vera Therapeutics | VERA | New Coverage | Outperform (N/A) |
13.45 (42.91) |
219.03% | Details | |
| 5/6/2021 | Ultragenyx Pharma | RARE | Upgrade | Outperform (In Line) |
101.85 (33.39) |
-67.22% | Details | |
| 11/24/2020 | Travere Therapeutics | TVTX | New Coverage | Outperform (N/A) |
24.87 (56.81) |
128.43% | Details | |
| 11/24/2020 | Enanta Pharmaceuticals | ENTA | New Coverage | Underperform (N/A) |
43.57 (39.47) |
-9.41% | Details | |
| 11/24/2020 | Ultragenyx Pharma | RARE | New Coverage | In Line (N/A) |
114.37 (33.39) |
-70.81% | Details | |
| 11/24/2020 | Translate Bio | TBIO | New Coverage | Outperform (N/A) |
18.32 (3.23) |
-82.37% | Details | |
| 11/24/2020 | Altimmune | ALT | New Coverage | Outperform (N/A) |
9.32 (3.04) |
-67.38% | Details | |
| 11/24/2020 | Madrigal Pharmaceuticals | MDGL | New Coverage | Outperform (N/A) |
114.87 (536.95) |
367.44% | Details | |
| 11/24/2020 | Insmed | INSM | New Coverage | Outperform (N/A) |
39.07 (106.62) |
172.89% | Details | |
| 11/24/2020 | Theravance Biopharma | TBPH | New Coverage | Outperform (N/A) |
17.21 (17.00) |
-1.22% | Details | |
| 11/23/2020 | Savara | SVRA | New Coverage | Outperform (N/A) |
1.18 (3.83) |
224.58% | Details | |
| 11/23/2020 | Innate Pharma S.A. | IPHA | New Coverage | Outperform (N/A) |
4.90 (1.84) |
-62.45% | Details |
